Need recent data on Zometa

PeggyDixon

Hi - I see my onc on Monday but at my last 2 visits, 6 and 12 months ago, I've been asking for Zometa as a preventative. She wanted to wait for some more studies to be finished. A few months ago there were some studies published and I sent them to her but she can't find them. She wants to read them before my Monday appt but - I can't find them either!! Does anyone have any recent study results or links to reports on Zometa in early-stage bc, particularly for post-menopausal women. I think it was the post-menopausal group she was waiting for.  THANKS!

I'm thinking she must be considering it because she is looking for the studies. Fingers crossed.

Peggy

NancyD

Here's a link to an article that references a Lancet report.

http://www.medicalnewstoday.com/articles/184134.php 

Mom3

I don't know about any articles so I'm sorry but I can't help there. But I did want to say that my doctor put me on Aredia about a year ago (similar to Zometa) b/c he said there were several studies in Europe that 'strongly confirmed' it helps in preventing a recurrence. I'm post menopausal too! I truly hope you find studies that confirm this b/c it would be wonderful if you got on it. All the best!

clariceak

My onc wasn't convinced last September, but has since changed her mind and I'm post menopausal.  Also my bones are crappy so that might be the tipping point.  Have you had a bone scan?

LISAA401

I am pre menopausal and I asked my onoc about studies showing early bc and biphosphates and preventions of bone mets. She had no problem ordering it.  My insurance actually covered it and I got Zomet  Monday even though we are using it off label for prevention. Kudos for whoever gave the auth from the insurance co. forward thinking.

PeggyDixon

Thanks guys for all your input...much appreciated. I still can't find the studies I thought I had a few months ago so won't have anything to bring in to show her; why oh why did I hide the info so well that I can't even find it!! lol

OneBadBoob

Hi Peggy--

I did a lot of research before I started on 4 mg. Zometa every 6 months for prevention of mets, and I am trying to locate my research.

Here is one link:

Another article:  http://www.nytimes.com/2009/02/12/health/research/12bone.html

http://mycanceradvisor.com/2009/07/24/zoledronic-acid-zometa-to-prevent-breast-cancer-recurrence/

I will keep looking for the studies and articles and post them if and when I find them.

Also, see this thread: http://community.breastcancer.org/forum/73/topic/750623?page=1#post_1781656

Jane - Dance as if no one is watching!!
Diagnosis: 7/7/2007, IDC, <1cm, Stage I, Grade 1, 0/2 nodes, ER+/PR+, HER2-

orange1

Hi Peggy,

I have scanned copies of the New England Journal of Medicine article on ABCSG-12, the large study of Zometa in premenopausal women that I can email to you - I need to send them through email - not BC.org because the article is scanned so I have to send it as an attachment.  Or if you are okay with the short version, below is an abstract from the ASCO annual meeting with updated results.

 http://abstract.asco.org/AbstView_74_53921.html

Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.
Sub-category: Adjuvant TherapyCategory: Breast Cancer - Local-Regional and Adjuvant TherapyMeeting: 2010 ASCO Annual Meeting
Citation: J Clin Oncol 28:7s, 2010 (suppl; abstr 533)Abstract No: 533 Attend this session at the ASCO Annual Meeting!Session: Breast Cancer - Local-Regional and Adjuvant TherapyType: Poster Discussion SessionTime: Monday June 7, 2:00 PM to 6:00 PMLocation: S403Discussion: Monday June 7, 5:00 PM to 6:00 PMLocation: N Hall B1Personalize your Annual Meeting experience with a suggested or customized itinerary!
Author(s): M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, P. C. Dubsky, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil; Medical University of Vienna, Vienna, Austria; Paracelsus University of Salzburg, Salzburg, Austria; Medical University of Graz, Graz, Austria; Hospital of the Sisters of Mercy, Linz, Austria; Medical University of Vienna, General Hospital, Vienna, Austria; University of Schleswig-Holstein, Kiel, Germany; University Hospital Salzburg, Salzburg, Austria
Abstract:

Background: The ABCSG-12 trial examined the efficacy of ovarian suppression using goserelin in combination with anastrozole (ANA) or tamoxifen (TAM) ± zoledronic acid (ZOL) in premenopausal patients (pts) with endocrine-responsive breast cancer (EBC). The first efficacy analysis at ASCO 2008, showed no difference between TAM and ANA, but adding ZOL significantly reduced the risk of disease-free survival (DFS) events by 36% (p = 0.01). Longer follow-up is now available. Methods: 1,803 premenopausal pts with EBC were randomized to goserelin (3.6 mg q 28 d) and TAM (20 mg/d) or ANA (1 mg/d) ± ZOL (4 mg q 6 mo). Endpoints were DFS and overall survival (OS); both were analyzed using log-rank test and Cox models. Compared with 2008 data, we now report on 34% more DFS events and 55% more deaths, based on a December 1, 2009, data cutoff. Results: With a median follow-up of 62 mo, 183 DFS events and 65 deaths were reported. Overall, ZOL reduced the risk of DFS events by 32% (HR = 0.68 [95% CI = 0.51, 0.91]; p = 0.009). The risk reduction by ZOL was identical in the TAM and ANA strata (HR = 0.68 [0.44, 1.05] for TAM, HR = 0.68 [0.45, 1.02] for ANA), and for N- and N+ pts. With respect to OS, ZOL reduced the risk of death by 34% (HR = 0.66 [0.41, 1.09]; 0 = 0.10). The OS benefit was even more pronounced in the N+ subgroup (HR = 0.61; p= NS). There was no difference in DFS between pts who received TAM alone vs ANA alone (HR = 1.11 [0.84, 1.50]; P = .44). However, ANA pts did worse with respect to OS (HR = 1.74 [1.05, 2.87]; p = 0.03) vs TAM, probably due to differences in post-relapse treatment. Treatments were generally well tolerated. There was no case of renal failure or osteonecrosis of the jaw (ONJ).Conclusions: With longer follow-up of ABCSG-12, the addition of ZOL (4 mg q 6 mo) consistently improves both DFS and OS in the ANA and TAM subgroups, and in N+ and N- pts. There was no DFS difference between ANA and TAM, but ANA pts had inferior OS vs TAM; probably because ANA pts lack palliative aromatase inhibitor treatment. Based on these results and the known anticancer activity of adjuvant ZOL, this treatment should be considered for premenopausal pts with EBC.